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ABSTRACT
Objective: To develop a simple, rapid, precise, accurate, sensitive spectrophotometric methods (A and B) were developed for simultaneous estimation 
and validation of vilanterol (VTL) and fluticasone furoate (FFE) in pure and tablet dosage forms.
Methods: Method A is a simultaneous equation method and Method B is a first-order derivative spectrophotometric method. Pure drug samples of 
VTL and FFE were dissolved in a mixture of methanol and ethanol in the ratio of 1:1 (v/v) and found to have absorbance maxima at 231 nm for VTL 
and 260 nm for FFE, respectively.
Results: The linearity lies between 2.5-10 µg/ml for VTL and 10-60 µg/ml for FFE in these two methods (A and B). The correlation coefficient (r2) 
was found to be 0.999 for both VTL and FFE, the limit of detection and limit of quantification were found to be 0.015 and 0.05 µg/ml for VTL and 0.05 
and 0.2 µg/ml for FFE, respectively. The results of analysis have been validated statistically by recovery studies as per International Conference on 
Harmonization guidelines.
Conclusion: The two methods A and B showed good reproducibility and recovery with %RSD <2. Hence, both methods were found to be rapid, 
specific, precise, and accurate and can be successfully applied for the routine analysis of VTL and FFE in pure and combined dosage form.
Keywords: Fluticasone furoate, Vilanterol, Derivative spectrophotometric, Simultaneous equation method, Method development and validation.
INTRODUCTION
Fluticasone furoate (FFE) [(6α,11β,16α,17α)-6,9-difluoro-17-{[(fluoro-
methyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1,4-
dien-17-yl 2-furancarboxylate] and vilanterol (VTL)[4-{(1R)-2-[(6-
{2-[(2,6-Dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2 
hydroxymethyl)phenol] are available in a combined dosage form (trade 
names BreoEllipta and RelvarEllipta) approved by USFDA in 2013 used 
for the treatment of chronic obstructive pulmonary disease (COPD), 
including chronic bronchitis and emphysema and asthma [1]. FFE is a 
synthetic trifluorinated corticosteroid with potent anti-inflammatory 
activity used for long-term maintenance treatment of airflow 
obstruction in patients with COPD, including chronic bronchitis and 
emphysema [2]. It is also approved for the treatment of asthma [3,4], 
nasal allergy symptoms, including congestion, sneezing, itching, and 
runny nose. It works by reducing inflammatory reactions in the nasal 
airway in response to allergens and irritants in the air. VTL is a selective 
long-acting beta2-adrenergic agonist used for once daily treatment of 
COPD and asthma [5,6]. Literature survey revealed that there is only 
a single ultra-performance liquid chromatography method developed 
for determination of FFE and benzalkonium chloride [7]. Since no 
spectrophotometric method is reported for simultaneous estimation, 
the present study is aimed to develop two spectrophotometric methods, 
i.e., first-order derivative spectrophotometric and simultaneous 




Analytically pure FFE and VTL were obtained as gift samples from 
reputed pharmaceutical companies. Methanol, (Merck, Mumbai, India) 
water was of HPLC grade, while ethanol used for the preparation 
of mobile phase was of analytical grade (Merck Specialties Private 
Limited, Mumbai, India). Formulations of BreoEllipta inhalation 
powder contains a combination of fluticasone and VTL containing 
labeled amount of fluticasone 100 µg-VTL 25 µg were procured from 
the local market.
Equipment
A double beam ultraviolet (UV)/visible spectrophotometer model 
Tec comp UV-2301 was used to carry out spectral analysis and the 
data were recorded by Hitachi software. Standard and sample drugs 
were weighed by using Denver electronic analytical balance (SI-234). 
A Synchronies C-18 (250 mm × 4.6 mm, 5 μm) column was used as a 
stationary phase.
Preparation of standard drug solution
Amount of 10 mg of standard drug VTL and FFE were weighed 
separately and dissolved in 5 ml diluent then transferred to a 10 ml 
volumetric flask sonicate it for 5 minutes, finally volume was made 
up to the mark with same solvent to make 1000 µg/ml stock solution. 
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i4.16748
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Fig. 1: Chemical structures of fluticasone furoate and vilanterol
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From this, 1 ml was again diluted to 10 ml to get a concentration of 
10,000 µg/ml solution of VTL and FFE were obtained separately. From 
the solution, required concentrations were prepared separately, and 
then, 1 ml from each of the solution was mixed to obtain a combined 
solution for the simultaneous estimation of VTL and FFE.
Method A: Simultaneous equation method
From the stock solution of 1000 µg/ml, working standard solutions 
of drugs were prepared by appropriate dilution and were scanned in 
entire UV range to determine the absorbance max. VTL has maximum 
absorbance at 231 nm while FFE at 260 nm (Fig. 2). Standard solutions 
were prepared having concentration 2.5-15 µg/ml for VTL and 
10-60 µg/ml for FFE. At the absorbance’s of these standard solutions, 
calibration curves were plotted at these wavelengths. Two simultaneous 




ax1 = Absorptivity of VTL at 231 nm
ax2 = Absorptivity of VTL at 260 nm
ay1 = Absorptivity of FFE at 260 nm
ay2 = Absorptivity of FFE at 231 nm
A1 and A2 are the absorbance of the diluted sample at 231 nm and 
260 nm respectively.
Method B: First-order derivative spectrophotometric method
The absorption spectra thus obtained by working standard solutions 
of VTL and FFE in the wavelength range of 200-400 nm against solvent 
methanol and ethanol in the ratio of 1:1 (v/v) as blank were derivatized 
from first order. From the overlay spectra of both the drugs (Fig. 3), 
wavelengths selected for quantitation were 231 nm was used for VTL 
and 260 nm was used for FFE. The proposed method was validated 
according to the United States Pharmacopeia and International 
Conference on Harmonization guidelines [10-12] in terms of linearity 
and range, precision, accuracy.
RESULTS AND DISCUSSION
Method A: Simultaneous equation method
Study of overlain spectra shows that VTL has maximum absorbance at 
231 nm while FFE at 260 nm, respectively. The linearity with absorbance 
in the range 2.5-15 μg/ml for VTL and 10-60 μg/ml for FFE at their 
respective maxima was validated by least square method. Linearity 
results were presented in Table 1; calibration graphs were presented in 
Fig. 4. The accuracy of the method was determined by calculating mean 
percentage recovery. It was determined at 50,100 and 150% level. The 
percentage recovery ranges from 98.5 to 99.2 for VTL and 98.22-99.70 
Fig. 2: Overlay spectra of vilanterol and fluticasone furoate
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for FFE, respectively. Precision was calculated as repeatability 
(%RSD <2) and inter and intraday variations (%RSD <2) for both drugs. 
The proposed methods were found to be simple, accurate and rapid 
for the routine determination of VTL and FFE in tablet formulation. 
Marketed brand of the tablet was analyzed, and the amount of drug 
determined by proposed methods was found to be 99.07-98.62 for VTL 
and FFE, respectively (Table 2). The method can be successfully used 
for simultaneous estimation of VTL and FFE in combined dosage form.
Method B: First-order derivative spectrophotometric method
Six points calibration curve were obtained in a concentration range 
from 2.5 to 15 μg/ml for VTL and 10-60 μg/ml for FFE, respectively. 
The response of the drug was found to be linear in the investigation 
concentration range and the linear regression equation was y = 0.000245x 
- 0.00047 with correlation coefficient (r2) 0.999 for VTL and y = 8E-05x + 
0.001 with correlation coefficient (r2) 0.999 for FFE (Table 3 and Fig. 5). 
The precision results were found to be within the limit where %RSD 
values for VTL found to be 0.723, 1.255, and 0.626 for intraday, interday 
and ruggedness studies. And also %RSD values for VTL found to be 0.411, 
0.22 and 0.26 for intraday, interday, and ruggedness studies. Recovery 
results also found within the validation limit that percentage of recovery 
are 98.6-100.24 for VTL and 99.55-100.75 for FFE, respectively.
Table 1: Results of linearity
VTL FFE
Concentration Absorbance Concentration Absorbance
2.5 0.181±0.002 10 0.231±0.003
5 0.343±0.001 20 0.423±0.003
7.5 0.499±0.005 30 0.629±0.002
10 0.637±0.008 40 0.849±0.003
12.5 0.795±0.005 50 1.028±0.011
15 0.961±0.002 60 1.246±0.012
The values given in table are the average±standard deviation for three replicate 
measurements. VTL: Vilanterol, FFE: Fluticasone furoate
Fig. 4: Calibration graph of vilanterol and fluticasone furoate
Fig. 5: Calibration graph of vilanterol and fluticasone furoate
Table 2: Formulation analysis VTL and FEE by proposed methods 
Method Drug Brand 
name
Labeled claim µg/ml Amount prepared µg/ml Amount found µg/ml % assay
Simultaneous equation 
method
VTL BreoEllipta 25 15 14.86±0.04041 99.0667
Fluticasone 100 60 59.17±0.075 98.6167
Derivative method VTL BreoEllipta 25 15 14.91±0.0265 99.40
Fluticasone 100 60 59.43±0.0153 99.05
The values given in table are the average±standard deviation for three replicate measurements. VTL: Vilanterol, FFE: Fluticasone furoate
Table 3: Results of linearity
VTL FFE
Concentration Absorbance Concentration Absorbance
2.5 0.00015±1E-06 10 0.00201±1.1547E-05
5 0.00073±1E-05 20 0.00278±0.000010
7.5 0.00139±0.000011 30 0.00362±0.000011
10 0.00198±0.000013 40 0.00445±0.000016
12.5 0.00257±0.000010 50 0.00532±0.000014
15 0.00321±0.000012 60 0.00605±0.000019
The values given in table are the average±standard deviation for three replicate measurements. VTL: Vilanterol, FFE: Fluticasone furoate
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Analysis of tabled formulation
About 10 tablets were weighed and powdered. The quantity of powder 
containing the equivalent of about 25 µg/ml of VTL and 100 µg/ml of FFE 
was weighed accurately into 100 ml volumetric flask. A volume of 50 ml 
of the solvent was added, sonicated for 20 minutes with intermediate 
shaking, diluted up to the mark with the solvent and mixed, filtered 
through 0.22 µm filter. Further, it is diluted to achieve concentrations 
of 15 µg/ml of VTL and 60 µg/ml of FFE. Analysis of tablet formulation 
BreoEllipta was carried out and the amount recovered was expressed 
as percentage amount of tablet claim (Table 3). The percentage 
recovery for VTL is 99.40 and FFE is 99.05, respectively. The method 
can be successfully used for simultaneous estimation of VTL and FFE in 
combined dosage form.
CONCLUSION
The proposed methods (A and B), i.e., simultaneous equation method 
and derivative method are found to be very simple and can be 
performed using any spectrophotometer and does not require much 
costly instruments. It also shows good linearity values and sensitivity. 
Thus, the methods are applicable for simple and economic estimation 
of VTL and FFE in their pharmaceutical dosage forms. Finally, it is also 
concluded that this was the first method developed in this combination 
of drugs VTL and FFE in their pharmaceutical dosage forms.
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